Skip to main content
OpenTrials
Completed

NCT Number: NCT00803400

Efficacy of Aerobic Exercise Added to Alprazolam in Panic Disorder Treatment

The purpose of this study is to determine whether the combination of aerobic physical exercise and alprazolam in patients with panic disorder has a better therapeutic response than the treatment with alprazolam alone.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Panic Disorder Anxiety Disorders Behavior Mental Disorders Motor Activity

Age range

20 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Psychiatry Academic Unit at J.A.Fernandez Hospital, University of Buenos Aires Medicine School Department of Mental Health

Buenos Aires, Buenos Aires F.D., 1425, Argentina

About this study

We have observed in our clinical practice that patients who practiced aerobic physical exercise had faster remissions and better improvement in their treatments that those who did not. There are also some scientific studies that included physical exercise in the treatment for panic disorder and compared them to other single pharmacological treatments.

So our objective will be to compare the efficacy of a pharmacological monotherapy (alprazolam), that is one of the options for the pharmacological treatment of panic disorder, with other treatment such as the combination of aerobic physical exercise and alprazolam, and to determine if this combination results in a better therapeutic response.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with panic disorder scored between 20 and 30 by the Hamilton Anxiety Rating Scale/14. (Baseline scale scores were measured during the first interview and diagnoses were made by a psychiatrist using the Structured Clinical Interview for DSM IV).
  • Good physical health and normal results determined on a previous physical examination and routine laboratory tests (renal, hepatic, hematological and thyroid function).
  • Patients who completed a written informed consent form (which was obtained from every included patient and had been fully explained before the procedure).

Exclusion criteria

  • A history of some kind of recent somatic disease.
  • Diagnosis of some other type of associated or psychiatric disease of axis I of DSM IV, such as affective disorders, drug dependency.
  • Hamilton Anxiety Scale lower than 20 points or higher than 30.
  • Use of some other type of medication or treatment (including psychotherapy) or having received it during last past 3 months.
  • Patients who could not complete the clinical examination
  • Patients who have not accepted to complete or sign the written informed consent.
  • Pregnant patients or in lactation. (A pregnancy test was performed for women in fertile age)
  • Patients with history of rejection to the used drug.

Treatment and study plan

alprazolam

Drug

The patients assigned to the pharmacological plan will receive 4 mg alprazolam daily for 12 weeks. Two weeks after the first interview they have their first baseline psychiatric control, where all the patients are tested.

Then, at the same visit, all the patients are indicated 4 mg of alprazolam. The dose is gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12.

Other names: Non exercise group

Alprazolam + Aerobic exercise

Drug

The patients assigned to exercise have to pass an ergometric test to determine their functional capacity expressed in METs for future exercise indication.

Two weeks after the first interview they have their first baseline psychiatric control and at the same time they are indicated a 4 mg dose of alprazolam, gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12.

Then they follow a protocolized aerobic exercise plan for this study during 12 weeks.

The type of selected exercise consists of a rapid walk for 30 minutes divided in stages.

After each stage the patient has to control his own heart frequency that has to be between 50 and 75% of their maximum to assure an aerobic condition (American Cardiological Association).

Other names: Exercise group

Primary outcomes

  1. Participants´Endpoint Change From Baseline in Hamilton Anxiety Rating Scale

    Time frame: 12 weeks

    The Hamilton Anxiety Rating Scale is a test that consists of 14 items measuring the severity of anxiety symptoms. Each item is rated on a 5-point ordinal scale, ranging from 0 (not present) to 4 (severe).

    Each of the 14 items measure both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety)with a total score range of 0-56, where 17 indicates mild severity, 18-24 mild to moderate severity, and 25-30 moderate to severe.

Secondary outcomes

  1. Participants´Endpoint Change From Baseline in Clinical Global Impression Severity Scale (CGI-S)

    Time frame: Baseline and 12 weeks

    The Clinical Global Impression Severity scale is a 7 point ordinal scale that rates the severity of the patient's illness, assessing on the severity of a patient's mental illness. It ranges from 1 to 7 (1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; 7, extremely ill).

  2. Participants´Endpoint Change From Baseline in Clinical Global Impression Improvement Scale (CGI-I)

    Time frame: Baseline and 12 weeks

    The Clinical Global Impression Improvement Scale is a 7 point ordinal scale that assesses how much the patient's illness has improved or worsened relative to a baseline state before the intervention. Rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.

Sponsors and collaborators

Lead sponsor

University of Buenos Aires

Other

Registry information

Official study title

Efficacy of Aerobic Exercise Added to Alprazolam in Panic Disorder Treatment: a Clinical Randomized Trial

Acronym: AEIPDT

Important dates

Study start
2008
Primary completion
2009
Study completion
2009
First posted
Dec 5, 2008
Registry last updated
Aug 19, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.